1. Medtech Insight
  2. >>Geography
  3. >>Europe

How “Regulatory Sandboxes” Offer Hope For New Technologies That Don’t Fit The Regulatory Mold

 
• By Amanda Maxwell

Globally, a new regulatory approach is being adopted increasingly frequently to understand and manage the growing number of cutting-edge medical technologies that sit uncomfortably within current regional or local regulatory structures.

Child playing with his truck toy on a sunny summer day sandy background.
A Safe Space For Regulators, Industry And Other Stakeholders To Play With Innovative Device Concepts • Source: Shutterstock

The pace of medtech innovation seems inexorable. So much advanced technology is becoming available, including through digital health and artificial intelligence, which is revolutionizing the way medical devices and IVDs are being designed and used. Medtech products that do not sit well within the confines of current regulatory environments are becoming increasingly commonplace.

With the promise of exciting new devices and services for patients, and lower costs for health services, there are a growing number of mechanisms being developed across the world

Key Takeaways
  • Regulatory sandboxes can help accelerate the development and commercialization of tricky-to-regulate innovative medical devices.
  • There is a need for harmonized eligibility criteria and guidance on the use of regulatory sandboxes in the medtech space

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

More from Geography

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.